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Malaria is the most important parasitic disease affecting
people living in and travelling to malaria endemic areas.'
Due to large scale global travel some people infected
with malaria may develop symptoms in countries where
malaria is not endemic. The risk of malaria for travellers
varies substantially depending on the area visited,
intensity of transmission, season and exposure factors,
including type of accommodation and itinerary.2
Malaria in humans is caused by four parasite species:
Plasmodium falciparum, P vivax, P ovale and P malariae.
Transmission is through the bite of an infected female
Anopheles mosquito. The incubation period varies from 7-30
days but chemoprophylaxis can prevent malaria or delay the
onset of illness by weeks or months, Delays characterise
P vivax and P ovale infections that produce dormant liver
stage parasites. The diagnosis of malaria depends on the
demonstration of parasites on a blood smear or a positive
blood antigen test. Commonly the clinical picture includes:
fever, chills, sweats, headaches, nausea and vomiting, and
malaise. Serious complications may accompany Pfalciparum
infections, particularly cerebral malaria, severe anaemia and
multi-organ failure. Malaria can be a fatal disease, However,
illness and death from malaria can be prevented.3
In Australia there were 799 notifications of malaria in
2004-2005 and none were reported as locally acquired.4
Papua New Guinea (PNG) is often implicated as the
source of infection among Australian travellers who
are diagnosed with malaria after overseas travel. 5 The
contribution of PNG to imported malaria in Australia has
ranged from 18-74% depending on the year studied and
region of study.5-7 Malaria is endemic in areas below 1800
m altitude in PNG, but can also occur in the highlands.8
All four malaria species are present in PNG with the
potentially life threatening P falciparum being present
throughout the malaria affected area at leve!s rarely found
outside sub-Saharan Africa. 9 The major malaria vectors
Anopheles farauti, A. koliensis and A. punctulatus are
found in coastal, low lying and highland areas of PNG.
These species have different biting activity, but peak
activity is between sunset and dawn. 1O
Unfortunately no effective vaccine against malaria is
currently commercially available." Travellers to malaria
endemic areas are advised to use effective personal
protection measures (PPM) and chemoprophylaxis.
The predominant site of action of many antimalarial
chemoprophylactic drugs is the blood stage rather than the
liver stage of the plasmodium parasite. These antimalarials
must be taken for 4 weeks after the last possible exposure
to malaria infection to enable action against blood stage
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parasites as they emerge from the liver.1,12
Personal protection measures include
bed nets and other materials impregnated
with insecticides, window and door screens,
knockdown insecticides indoors, covering
exposed areas with light coloured clothing
and shoes and socks, regularly applying an
insect repellent that contains N-diethyl-meta-
toluamide, using mosquito repellent coils and
vapourising mats, and avoiding exposure during
peak biting times. 13 Where PPM is combined
with appropriate chemoprophylaxis, the risk of
malaria infection can be reduced. 14 Australian
travellers rely on their general practitioner, or on
a GP specialising in travel medicine, for advice on
malaria prevention measures and for prescribing
malaria prophylaxis before travelling.
We report on the malaria risk experience of
a group of 38 Australians who travelled in three
teams to PNG at the end of August 2006 and
were involved in trekking and volunteer work.
After visiting PNG, four adult residents of rural
northern New South Wales were notified by an
alert GP with a diagnosis of malaria to the local
population health unit. The teams spent 15-17
nights in PNG, starting in Port Moresby, trekking
the Kokoda trail and finishing in the coastal area
near Gona. The groups participated in community
work in villages along the way.
The aims of the public health investigation
were to ensure that all members were aware of
the risks of developing malaria postexposure, to
detect and manage cases appropriately, and to
analyse contributing risk factors.
Method
A retrospective cohort investigation was
conducted. Contact details were obtained and all
members of the travel group were included in the
investigation. As this was a high priority public
health investigation under the auspices of the
New South Wales Public Health Act 1991, ethics
approval for the investigation was not required.
A standard questionnaire was used to
investigate signs and symptoms of malaria,
itinerary, types of accommodation, nature of
activities, use of PPMs, travel advice sought,
type of chemoprophylaxis prescribed, doses of
chemoprophylaxis taken, post-travel febrile illness
and medical advice given.
The use of six recommended PPM during
the high risk mosquito biting period between
dusk and dawn were investigated, namely
restricting outdoor activities, use of bed nets,
indoor knockdown insecticide, mosquito coils,
long clothing and topical repellent.
The duration of the investigation extended
over 3 months after the group's return from
PNG. Group members who had not experienced
any illness were advised to immediately seek
medical advice should they develop malaria
symptoms during the subsequent 3 months and
contact the population health unit. Two additional
group members were subsequently diagnosed
with malaria.
Diagnosis of malaria was made by
demonstrating malaria parasites in specifically
stained thick or thin blood films or by an
immunochromatographic rapid diagnostic test
(RDT) when blood films were not available. These
tests were conducted by an accredited reference
laboratory in Sydney, New South Wales.
Data were analysed using SPSS® for
Windows® (version 13 SPSS Inc, Chicago, III,
USA) for descriptive analysis of proportions, and
Fisher's exact test or likelihood ratios were used
for comparing proportions as appropriate.
Results
All 38 (100%) members of the travel group
participated in the investigation, and there
were no missing data. The median age of
group members was 45 years with a range
18-70 years. Of seven travellers who reported
developing a febrile illness on return to Australia,
six (86%, p<0.001) were subsequently
diagnosed with malaria. The onset of illness for
malaria cases ranged from 1-16 weeks after
return. Hospital treatment was required for five
of the malaria cases.
P vivax was identified in blood smears in 4/6
cases. One patient was positive for P vivax using
a RDT and included as a case. The remaining
case was presumptively diagnosed and treated
for malaria based on clinical grounds. This patient
had partially self treated during the trip and had
no other cause identified for this febrile illness.
The pathology for this patient remained negative
despite repeated testing.
Malaria was diagnosed in members of each
team: 1/21 of team one, 2/12 of team two
and 3/4 of team three (likelihood ratio =4.624,
p=O.10). Overnight accommodation included
staying briefly in a hotel, open air 'guesthouses'
(Figure 1), tents with or without screens, or
sleeping in the open. The duration in different
accommodation types did not differ significantly
between cases and noncases.
Twenty-five (65%) group members always
wore long sleeved shirts and trousers and 19
(50%) always used insect repellent during the
highest risk period. No members used all six
PPMs always or often (Table 1). Only one traveller
took their own bed net. There was no significant
difference in PPM use between malaria cases
and noncases in this group.
All but one of the group consulted a GP
before travel. Malaria infection occurred in 2/2
(100%) of the group members who did not
take chemoprophylaxis and 4/36 (11 %) people
who did take chemoprophylaxis (p=0.021).
Three types of chemoprophylaxis were used;
doxycycline by 28 (78%), mefloquine.by 6 (17%),
and atovaquone+proguanil by 2 (6%). Malaria
occurred in those using doxycycline (3/28) or
mefloquine (1/6) but there was no statistical
association with type of chemoprophylaxis used.
Five of the individuals using chemoprophylaxis
(14%) missed doses and only 12 (33%)
continued use for the recommended period
after leaving the malarious area (4 weeks for
doxycycline and mefloquine, and 7 days for
atovaquone+proguanil),15 None of the 12
individuals who took chemoprophylaxis for
the recommended period developed malaria
compared to 4/24 (17%) of those who terminated
chemoprophylaxis prematurely, either by choice
or by following the schedule prescribed by their
GP (likelihood ratio=3.489, p=0.062).
Most (30/38) members of the travel group
reported not seeing any mosquitoes during their
journey through PNG.
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e Malaria is the most important parasitic
disease affecting people living in and
travelling to malaria endemic areas.
G Pretravel consultations should
emphasise meticulous use of effective
chemoprophylaxis for the full recommended
period after return coupled with multiple
effective PPMs to reduce the risk of infection
and disease.
$ Malaria infection usually presents as a
febrile illness. In patients with inadequate
chemoprophylaxis use, disease onset may
be delayed for weeks or months.
period'), nature of accommodation and human
behavioural factors.3 It would be useful for GPs
who provide pre-travel advice or post-travel
assessment to have ongoing access to up-to-
date and reliable information on malaria risk and
prevention strategies.
This investigation was limited by the small
number of travellers in the cohort and the
delayed and self reported nature of risk and
protective factors.
Malaria infection usually presents as a
febrile illness. In patients with inadequate
chemoprophylaxis use, disease onset may be
delayed for weeks or months. Our investigation
demonstrates the importance of maintaining a
high index of suspicion for malaria in travellers
returning from malaria endemic countries, with
6n travellers in this cohort that developed fever
post-travel being diagnosed with clinical or
confirmed malaria. Being alert for possible clusters
of infection and timely notification can ensure
optimal clinical and public health management.
Number of PPMs alwaysl Malaria No malaria Total
often used
0 1 2 3
1 1 9 10
2 2 18 20
3 1 3 4
4 1 0 1
>5 0 0 0
Total 6 32 38
Chemoprophylaxis and PPMs remain integral
to malaria prevention. This investigation
documented infrequent use of multiple PPMs
even though travel occurred in an area known
to have malaria. Pretravel consultations should
emphasise the importance of combining
chemoprophylaxis with multiple effective PPMs
that limit mosquito exposure. 16
The 100% attack rate among people who did
not take any chemoprophylaxis is a compelling
argument for taking effective chemoprophylaxis
when visiting high risk malaria areas. This is
particularly important in rural locations in PNG
where available accommodation, as in the
current case, may not provide an adequate
barrier to Anopheles mosquitos feeding during
peak biting periods.
For travellers returning from a malaria
endemic area, including PNG, it is recommended
that chemoprophylaxis be continued for the
recommended period after travel to cover
infection acquired up to the final day of stay.
Irregular use has previously been linked with
malaria infection in Australian travellers.7 Our
investigation supports the importance of
counselling travellers that chemoprophylaxis
should be continued for the recommended
period post-travel. Each case of malaria in this
investigation occurred in a group member
who had taken either no chemoprophylaxis or
terminated their chemoprophylaxis earlier than
the recommended period.
Malaria risk varies over time, between
and within countries and is dependent
on a range of factors including climate, the
presence of Anopheles mosquitoes, malaria
parasites being able to complete their growth
cycle in the mosquitoes ('extrinsic incubation
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